Target intelligence / Profile preview

Delta-like ligand 3 (DLL3)

Target: DLL3
Molecular classification: Notch ligand

Overview

Delta-like ligand 3 (DLL3) is a Notch ligand involved in Notch signaling. Unlike other Notch ligands, DLL3 primarily acts as an inhibitor of Notch signaling. It is a therapeutic target in cancers with high DLL3 expression, particularly small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NENs).

Mechanism of action

DLL3 inhibition

Biological functions

Notch signalingCell differentiationCell proliferationCell survivalApoptosisSomitogenesis

Disease associations

CancerNeuroendocrine tumorigenesisJarcho-Levin syndrome

Safety considerations

Potential toxicities associated with targeted therapiesResistance to targeted therapies

Interacting drugs

Rovalpituzumab tesirine

Biomarkers

DLL3 expression level

Beyond the preview

Go deeper on Delta-like ligand 3 (DLL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta-like ligand 3 (DLL3).

Explore the full profile